Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease

Pancreas

Volumn 9, Issue 6, 1994, Pages 707-716

  Ritts, R E ^a   Nagorney, David M ^a   Jacobsen, Deborah J ^a   Talbot, Robert W ^b   Zurawski, Vincent R ^c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c Apollon Inc   (United States)

Author keywords

CA19 9; Gallbladder; Pancreas

Indexed keywords

CA 19-9 ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN SPECIFICITY; ARTICLE; BILIARY TRACT DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COMPARATIVE STUDY; FEMALE; FOLLOW-UP STUDIES; GALLBLADDER DISEASES; GALLBLADDER NEOPLASMS; HUMAN; LAPAROTOMY; MALE; MIDDLE AGE; PANCREATIC DISEASES; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 0028143266     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/00006676-199411000-00006     Document Type: Article

References (30)

1. DiMagno EP. Pancreatic cancer: a continuing diagnostic dilemma. Ann Intern Med 1979;90:847-8.
2. Go VLW, Taylor WF, DiMagno EP. Efforts at early diagnosis of pancreatic cancer: the Mayo Clinic experience. Cancer 1981;47:1698-703.
3. Silverstein MD, Richter JM, Podolsky DK, Warshaw AL. Suspected pancreatic cancer presenting as pain or weight loss: analysis of diagnostic strategies. World J Surg 1984;8: 839-45.
4. Richter JM, Christensen MR, Rustgi AK, Silverstein MD. The clinical utility of the CA 19-9 radioimmunoassay for the diagnosis of pancreatic cancer presenting as pain or weight loss. A cost effective analysis. Arch Intern Med 1989;149: 2292-7.
5. Podolsky DK, McPhee MS, Alpert E, et al. Galactosyltrans-ferase isoenzyme II in the detection of pancreatic cancer. Comparison with radiologic, endoscopic, and serologic tests. N Engl J Med 1981;304:1313-8.
6. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957-72.
7. Magnani J, Nilsson B, Brockhaus M, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-AT-fucopenteose II. J Biol Chem 1982;257:14365-9.
8. Itkowitz SH, Kim YS. New carbohydrate tumor markers. Gastroenterology 1986;90:491-1.
9. Koprowski H, Herlyn M, Steplwski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53-5.
10. Ritts RE Jr, Del Villano BC, Go VLW, Herberman RB, Klug TL, Zurawski VR Jr. Initial clinical evaluation for an immu-noradiometric assay for CA 19-9 using the NCI serum bank. Int J Cancer 1984;33:339.
11. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA 19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704-9.
12. Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA 19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986;90:343-9.
13. Del Villano BC, Brennan S, Brock P, et al. Radioimmuno-metric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1989;29:549.
14. Erdreich LS, Lee ET. Use of relative operating characteristic analysis in epidemiology. A method for dealing with subjective judgement. Am J Epidemiol 1981;114:649-62.
15. Sox HC Jr, et al. Measuring the accuracy of clinical data. In: Sox HC Jr, Blatt MA, Higgins MC, Marton KI, eds. Medical decision making. Boston: Butterworths, 1988:123-4.
16. Haglund C, Kuusela P, Roberts PJ. Tumor markers in pancreatic cancer. Ann Chir Gynaecol 1989;78:41-53.
17. Koelbl H, Schieder K, Neunteufel W, Bieglmayer C. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9, and CEA in patients with ovarian cancer. Neoplasma 1989;36:473-8.
18. Fabris C, Basso D, Piccoli A, et al. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer. J Med 1991;22:145-56.
19. Malesci A, Montorsi M, Mariani A, et al. Clinical utility of the serum CA 19-9 test for diagnosing pancreatic carcinoma in symptomatic patients: a prospective study. Pancreas 1992;7:497-502.
20. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma. Imaging techniques and tumor markers. Pancreas 1992;7:66-86.
21. Carlucci M, Zerbi A, Parolini D, et al. CT-guided pancreatic percutaneous fine-needle biopsy in differential diagnosis between pancreatic cancer and chronic pancreatitis. HPB Surg 1989;1:309-14.
22. DelMaschio A, Vanzulli A, Sironi S, et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. Radiology 1991;178:95-9.
23. Parker N, Makin CA, Ching CK, et al. A new enzyme-linked lectin/mucin antibody sandwich assay (CAM 17.1/WGA) assessed in combination with CA 19-9 and peanut lectin binding assay for the diagnosis of pancreatic cancer. Cancer 1992;70:1062-8.
24. Satake K, Chung Y-S, Umeyama K, Takeuchi T, Kim YS. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. Cancer 1991;68:149-52.
25. Tian F, Appert HE, Myles J, Howard JM. Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg 1992;215:350-5.
26. Safi F, Beger HG, Bittner R, Buchler M, Krautzberger W. CA 19-9 and pancreatic adenocarcinoma. Cancer 1986;57: 779.
27. Nardone DA. The serologic marker CA 19-9 and pancreatic cancer [Letter]. Ann Intern Med 1989;111:184-5.
28. Robles-Diaz G, Diaz-Sanchez V, Fernandez-del Castillo C, et al. Serum testosterone:dihydrotestosterone ratio and CA 19-9 in the diagnosis of pancreatic cancer. Am J Gastroenterol 1981;86(5):591-4.
29. Molina LM, Diez M, Cava MT, et al. Tumor markers in pancreatic cancer: a comparative clinical study between CEA, CA 19-9, and CA 50. Int J Biol Markers 1990;5:127-32.
30. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350-5.